TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04900818: Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Sponsor: I-Mab Biopharma US Limited · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 330 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$6,220,368

Rescue Site Savings

+$4,115,496

Unlock Full NCT04900818 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04900818 Rescue Dossier →